Clinical trials
Immunotherapy clinical trials
Below are recruiting immunotherapy clinical trials, each written for real people, not researchers. We’re tracking 747 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06198296RecruitingPhase 1
Armored CAR T cells for GPC3-positive solid tumors
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
Houston, TexasAges Up to 21 years - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT06159335RecruitingPhase 3
PET/MR scan for brain metastasis imaging
This trial uses a special PET/MR scan with a radioactive tracer to help tell the difference between tumor regrowth and changes from radiation treatment in people with brain metastases. It may help doctors make better treatment decisions.
Madison, WisconsinAges 18 years+ - NCT06149481RecruitingPhase 1/Phase 2
STAR15 immunotherapy for metastatic colorectal cancer
This trial tests a combination of four drugs (SX-682, TriAdeno vaccine, retifanlimab, and N-803) to see if they can help people with colorectal cancer that has spread. It may be an option if you have already tried at least two standard treatments or cannot take them.
Bethesda, MarylandAges 18–120 - NCT06132438RecruitingPhase 1
New immunotherapy for CMV-positive glioblastoma
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
Liverpool, New South WalesAges 18–100 - NCT06120374Recruiting
Immunotherapy plus radiation after surgery for upper tract cancer
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
BeijingAges 18 years+ - NCT06116032Recruiting
Immune profiling for cancer immunotherapy response
This trial studies immune system changes in cancer patients receiving immunotherapy, such as checkpoint inhibitors or cell therapies. It aims to understand why some people respond better than others.
Lebanon, New HampshireAges 18 years+ - NCT06113315Enrolling by invitation
Collecting samples and data from sarcoma patients on immunotherapy
This study collects tissue samples and medical data from people with sarcoma who are receiving or will receive immunotherapy. Its goal is to learn more about how these treatments work against sarcoma.
Basking Ridge, New JerseyAges Any age - NCT06128252Recruiting
Taurine with chemotherapy and immunotherapy for gastric cancer
This trial tests whether adding taurine to standard chemo-immunotherapy before surgery helps treat locally advanced gastric cancer. It may be an option for patients whose tumors are PD-L1 positive and can be fully removed with surgery.
Wuhan, HubeiAges 18–75 - NCT06098560Recruiting
ctDNA as a marker for immunotherapy in advanced colorectal cancer
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT03080974RecruitingPhase 2
Study tests immunotherapy plus electroporation for advanced pancreatic cancer
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Louisville, KentuckyAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+ - NCT06031233RecruitingPhase 4
Shorter infusion times for cancer immunotherapy drugs
This trial tests if giving common immunotherapy drugs over a shorter time is safe. It may mean less time in the clinic for you.
ZwolleAges 18 years+ - NCT06050733Recruiting
Gut bacteria and immunotherapy response in solid tumors
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Galveston, TexasAges 35–75 - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06026111Recruiting
Exercise during immunotherapy for lung cancer
This study tests if adding a structured exercise program can help people with non-small cell lung cancer who are already on immunotherapy. It is for people who are not currently very active and are willing to travel to Dana-Farber Cancer Institute for some visits.
Boston, MassachusettsAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Phoenix, ArizonaAges 18 years+ - NCT05978193RecruitingPhase 2
Radiation plus chemo-immunotherapy for advanced esophageal cancer
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
ShanghaiAges 18 years+ - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT05965557Recruiting
Markers that predict response to immunotherapy before lung surgery
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
ShanghaiAges 18–80 - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunotherapy?
- Yes. Clin2 currently lists 747 recruiting immunotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.